PD33-07 SAFETY AND EFFECTIVENESS OF AUTOLOGOUS ADIPOSE TISSUE DERIVED STROMAL VASCULAR FRACTION INJECTION FOR TREATMENT OF EERECTILE DYSFUNCTION

You have accessJournal of UrologyStem Cell Research: Stem Cell Research I1 Apr 2018PD33-07 SAFETY AND EFFECTIVENESS OF AUTOLOGOUS ADIPOSE TISSUE DERIVED STROMAL VASCULAR FRACTION INJECTION FOR TREATMENT OF EERECTILE DYSFUNCTION Maya Epifanova, Michael Chaliy, Ilya Eremin, Andrey Pulin, Irina Nadelyaeva, Badria Gvasaliya, Sergey Artemenko, and Maksim Durashov Maya EpifanovaMaya Epifanova More articles by this author , Michael ChaliyMichael Chaliy More articles by this author , Ilya EreminIlya Eremin More articles by this author , Andrey PulinAndrey Pulin More articles by this author , Irina NadelyaevaIrina Nadelyaeva More articles by this author , Badria GvasaliyaBadria Gvasaliya More articles by this author , Sergey ArtemenkoSergey Artemenko More articles by this author , and Maksim DurashovMaksim Durashov More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2018.02.1562AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Our team developed a novel treatment strategy of erectile dysfunction (ED). Stromal vascular fraction (SVF) is considered as promising cell-based product for treatment of wide variety of diseases without the need of cell expansion in vitro. SVF injection was proved to be safe in numerous preclinical and clinical trials. The aim of the present study was to evaluate safety and efficacy of intracavernosal injection of SVF (NCT02472431). METHODS The study included 12 men with vasculogenic ED (mean age 47 years, IIEF-5<21). Effect of pharmacological intervention (PDE-5) was insufficient. Aspirated adipose tissue was processed using Celution 800/CRS System (Cytori Therapeutics Inc). Obtained cells were resuspended in 2.0 mL of Hartmann's solution. SVF injection was performed on lateral surface of penis bilaterally proximally into the middle and distal parts of corpus cavernosum. Equal portions of ADRC suspension injected into both corpora cavernosa. Following methods: doppler ultrasonography combined with intracavernosal prostaglandin-E1 injection; EndoPAT; International Index of Erectile Function (IIEF-5); Sexual Encounter Profile (SEP); Erection Hardness Score (EHS). RESULTS Intracavernosal injections of SVF were well tolerated by all patients. Neither adverse events nor complications have been detected in the clinical study. 24 weeks after SVF injection systolic speed increased and reached on the left cavernous artery avg 36 (32 to 46) cm/s, the right cavernous artery avg 35 (30 to 49,5) cm/s; Resistance Index - the left cavernous artery 0,91 (0,83 to 0,97), the right cavernous artery 0,91 (0,85 to 0,97); IIEF-5-17 (13 to 20); EHS-3 (2 to 4); SEP-3 (2 to 4); EndoPAT - ?ndothelial function was significantly improved 6 months after the procedure. CONCLUSIONS The study showed that effects of SVF injection contribute to recovery of erectile function. Results were confirmed by improvement of arterial blood flow and recovery of endothelial function. The proposed technique is safe and effective therefore it may be recommended as alternative treatment method of ED. Patent granted RU2622757. Now we are planning to start multicenter phase 2b study. © 2018FiguresReferencesRelatedDetails Volume 199Issue 4SApril 2018Page: e653 Advertisement Copyright & Permissions© 2018MetricsAuthor Information Maya Epifanova More articles by this author Michael Chaliy More articles by this author Ilya Eremin More articles by this author Andrey Pulin More articles by this author Irina Nadelyaeva More articles by this author Badria Gvasaliya More articles by this author Sergey Artemenko More articles by this author Maksim Durashov More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...